Abbott nabs £100m lab contract in Scotland

Abbott Labs has won a contract worth over £100m ($155m) to provide laboratory services to NHS Greater Glasgow and Clyde. The seven-year deal, said to be the biggest lab contract in the world, will see Abbott provide reagents for biochemistry, haematology, microbiology, genetic testing and pathology services. In addition, the company will equip the new "super lab" currently under construction at the Southern General hospital in Glasgow. The five-storey lab, covering 25,000 square metres, will cost £75m on completion, and is due to open in spring 2012. “The importance of signing this contract with Abbott Labs cannot be underestimated," stated Robert Calderwood, chief executive of NHS Greater Glasgow and Clyde, adding that it awarded the contract to Abbott as it was the world leader in its field.

Abbott Labs has won a contract worth over £100m ($155m) to provide laboratory services to NHS Greater Glasgow and Clyde. The seven-year deal, said to be the biggest lab contract in the world, will see Abbott provide reagents for biochemistry, haematology, microbiology, genetic testing and pathology services. In addition, the company will equip the new "super lab" currently under construction at the Southern General hospital in Glasgow. The five-storey lab, covering 25,000 square metres, will cost £75m on completion, and is due to open in spring 2012. “The importance of signing this contract with Abbott Labs cannot be underestimated," stated Robert Calderwood, chief executive of NHS Greater Glasgow and Clyde, adding that it awarded the contract to Abbott as it was the world leader in its field.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.

Execs On The Move: July 14–18, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.